SPRY ARS Pharmaceuticals, Inc.companySEC Filings & Insider Trading Activity 2026
Latest ARS Pharmaceuticals, Inc. (SPRY) SEC EDGAR filings in 2026, including the most recent 10-K annual report filed on March 9, 2026, a 10-Q quarterly report filed on May 15, 2026, an 8-K current report filed on July 17, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for ARS Pharmaceuticals, Inc. (SPRY) (SEC CIK 1671858), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
Go deeper on ARS Pharmaceuticals, Inc.
Ask AI about SPRY filings. Chat with the 10-K, 10-Q, and 8-K for instant answers on financials, risks, and guidance.
Track institutional money. See which funds are building or cutting SPRY positions, quarter over quarter.
Catch cross-signals. Spot when insider buying, fund accumulation, and activist stakes line up on SPRY.
Recent 8-K FilingsCurrent Reports
AI-powered analysis of ARS Pharmaceuticals, Inc. (SPRY) 8-K current reports disclosing material events.
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Jul 17, 2026 | - | - | - |
8-K | Jul 7, 2026 | - | - | - |
8-K | Jun 25, 2026 | - | - | - |
10-Q | May 15, 2026 | Mar 31, 2026 | - | |
8-K | May 15, 2026 | - | - | |
8-K | May 13, 2026 | - | - | |
10-K | Mar 9, 2026 | Dec 31, 2025 | - | |
8-K | Mar 9, 2026 | - | Analysis | - |
10-Q | Nov 10, 2025 | Sep 30, 2025 | - | |
10-Q | Aug 13, 2025 | Jun 30, 2025 | - | |
10-Q | May 14, 2025 | Mar 31, 2025 | - | |
10-K | Mar 20, 2025 | Dec 31, 2024 | - | |
10-Q | Nov 13, 2024 | Sep 30, 2024 | - | |
10-Q | Aug 6, 2024 | Jun 30, 2024 | - | |
10-Q | May 9, 2024 | Mar 31, 2024 | - | |
10-K | Mar 21, 2024 | Dec 31, 2023 | - | |
10-Q | Nov 9, 2023 | Sep 30, 2023 | - | |
SC 13D | Aug 31, 2023 | - | - | |
10-Q | Aug 10, 2023 | Jun 30, 2023 | - | |
10-Q | May 15, 2023 | Mar 31, 2023 | - | |
10-K | Mar 23, 2023 | Dec 31, 2022 | - | |
SC 13D | Nov 21, 2022 | - | - | |
SC 13D | Nov 18, 2022 | - | - | |
SC 13D | Nov 18, 2022 | - | - | |
SC 13D | Nov 18, 2022 | - | - |
13F Fund Holdings: Quarterly Trend
Latest: Q1 2026Aggregate SPRY share value held by 13F filers tracked by SignalX, by quarter.
- Millennium Management+2.81M (+89%)
- Third Point LLC+443.8K (+80%)
- State Street Corp+421.4K (+13%)
- Northern Trust+8.3K (+2%)
- BNY Mellon+1.1K (+1%)
- Morgan Stanley235.7K (-43%)
- Citadel Advisors LLC201.0K (-10%)
- Bank of America Corp196.4K (-41%)
- Goldman Sachs Group87.8K (-11%)
- BlackRock73.1K (-1%)
- Franklin Resources+3.28M
- AQR Capital Management+25.9K
- Fifth Third Bancorp+225
- Vanguard Group Inc−3.51M
- JPMorgan Chase & Co−417.1K
- Principal Financial Group−112.8K
- Invesco Ltd−37.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 156 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe.
Frequently Asked Questions
What are the latest SPRY SEC filings in 2026?
ARS Pharmaceuticals, Inc. (SPRY) has filed a 10-K annual report on March 9, 2026, a 10-Q quarterly report on May 15, 2026, an 8-K current report on July 17, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did SPRY file its most recent 10-K annual report?
ARS Pharmaceuticals, Inc. (SPRY) filed its most recent 10-K annual report on March 9, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view SPRY 10-Q quarterly reports?
ARS Pharmaceuticals, Inc. (SPRY)'s most recent 10-Q quarterly report was filed on May 15, 2026. SignalX displays every SPRY 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has SPRY filed recently?
ARS Pharmaceuticals, Inc. (SPRY)'s most recent 8-K was filed on July 17, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find SPRY insider trading activity (Form 4)?
SignalX aggregates every SPRY Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does SPRY file with the SEC?
ARS Pharmaceuticals, Inc. (SPRY) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new SPRY filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for ARS Pharmaceuticals, Inc. (SPRY).
What is SPRY's SEC CIK number?
ARS Pharmaceuticals, Inc. (SPRY)'s SEC CIK (Central Index Key) number is 1671858. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1671858 to look up all SPRY filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Stay on top of ARS Pharmaceuticals, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 44+ filings.